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Abstract
Background: Cancer cells undergo massive alterations to their DNA methylation patterns that result in aberrant
gene expression and malignant phenotypes. However, the mechanisms that underlie methylome changes are not
well understood nor is the genomic distribution of DNA methylation changes well characterized.
Results: Here, we performed methylated DNA immunoprecipitation combined with high-throughput sequencing
(MeDIP-seq) to obtain whole-genome DNA methylation profiles for eight human breast cancer cell (BCC) lines and
for normal human mammary epithelial cells (HMEC). The MeDIP-seq analysis generated non-biased DNA
methylation maps by covering almost the entire genome with sufficient depth and resolution. The most
prominent feature of the BCC lines compared to HMEC was a massively reduced methylation level particularly in
CpG-poor regions. While hypomethylation did not appear to be associated with particular genomic features,
hypermethylation preferentially occurred at CpG-rich gene-related regions independently of the distance from
transcription start sites. We also investigated methylome alterations during epithelial-to-mesenchymal transition
(EMT) in MCF7 cells. EMT induction was associated with specific alterations to the methylation patterns of gene-
related CpG-rich regions, although overall methylation levels were not significantly altered. Moreover,
approximately 40% of the epithelial cell-specific methylation patterns in gene-related regions were altered to those
typical of mesenchymal cells, suggesting a cell-type specific regulation of DNA methylation.
Conclusions: This study provides the most comprehensive analysis to date of the methylome of human mammary
cell lines and has produced novel insights into the mechanisms of methylome alteration during tumorigenesis and
the interdependence between DNA methylome alterations and morphological changes.
Background
DNA methylation is an indispensable epigenetic modifi-
cation of mammalian genomes. In mammals, it occurs
predominantly at CpG dinucleotides which are sparsely
distributed through the genome except at short genomic
regions called CpG islands (CGIs) [1]. The state of CpG
methylation regulates and stabilizes chromatin structure,
and possibly regulates accessibility of these DNA regions
to the transcription machinery [2]. DNA methylation is
essential to diverse processes such as development,
X-inactivation, and imprinting [3-5]. Alterations to the
normal patterns of DNA methylation are linked to
many human diseases, such as cancer [6]. Many studies
have explored the aberrant patterns of DNA methylation
in cancers, as they might possibly be of value as cancer
cell markers, markers of tumor prognosis, predictors of
response to chemotherapy, and therapeutic targets
[7-10]. Human tumors have been shown to undergo a
massive loss of DNA methylation, but also to become
hypermethylated at certain gene promoters [11]. How-
ever, the entire genomic distribution of aberrant methy-
lations and the molecular mechanisms underlying
the methylome alterations in cancers remain unclear,
mainly due to the limitations of existing techniques for
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For example, the conventional strategies using methyla-
tion-sensitive restriction enzymes require high-molecu-
lar-weight DNA and are limited by the sequence
context of the chosen enzyme.
Recently an important technical advance for analyzing
DNA methylation was made by using immunoprecipita-
tion with an antibody against 5-methylcytosine to enrich
methylated DNA fragments [8]. This methyl-DNA
immunoprecipitation (MeDIP)-based approach enables
the rapid identification of multiple CpG sites universally,
and it can be combined with gene-by-gene PCR detec-
tion and with several promoter, CGI and tiling microar-
rays [13-16]. However, predefined CGIs cover only 7.4%
of all CpGs in the human genome and the entire human
genome is not yet represented in any microarray. Analy-
sis of DNA methylation has also been advanced recently
by the application of high-throughput DNA sequencing
technology that allows robust, quantitative, and cost-
effective functional genomic strategies. MeDIP in con-
junction with high-throughput sequence (MeDIP-seq)
provides a genome-wide mapping technique that has
successfully been used to profile the global DNA methy-
lation patterns of mature human spermatozoa genome
[17]. Bisulphite sequencing has also been combined with
high-throughput sequence (BS-seq) to describe the 120
Mb Arabidopsis DNA methylome [18,19]. In addition,
BS-seq was recently applied to the human DNA methy-
lome [20]. Unfortunately, it still remains too hard work
to apply BS-seq on a multiple comparative analysis of
methylomes in mammalian genomes.
In this study, we used MeDIP-seq to investigate the
whole-genome distribution of aberrant DNA methyla-
tion in eight breast cancer cells (BCC) lines and com-
pared these with the methylation patterns of normal
human mammary epithelial cells (HMEC). Furthermore,
to investigate the mechanisms of methylome alteration
and determine the effects of such changes on the mor-
phology of BCC lines, we identified alterations to the
methylation profile that occurred during the epithelial-
to-mesenchymal transition (EMT) in MCF7 cells treated
with TGFb and TNFa. Using this experimental
approach, we obtained novel insights in to the molecular
and genetic mechanisms of methylome alterations in
BCC lines and their functional association with cancer
phenotype.
Results
High-throughput sequencing analysis of MeDIP DNA
We profiled the genome-wide DNA methylation status
of normal and cancerous mammary cells by first gener-
ating MeDIP-enriched DNA libraries. Real-time quanti-
tative PCR was used for several genomic regions that
included known methylated or unmethylated promoters
to confirm that MeDIP specifically enriched methylated
DNA and efficiently removed unmethylated DNA (Addi-
tional file 1a). Immunoprecipitated fractions were sub-
jected to high-throughput sequencing using an Illumina
Genome Analyzer to obtain comprehensive methylation
maps. The influence of genomic amplifications and dele-
tions in the BCC lines was investigated by high-through-
put sequencing of input DNA fragments from each
samples, with the exception of MDAMB453 and
MRKnu1 which yielded an insufficient number of reads.
We obtained 97 million uniquely mapped singleton
reads and 11 million paired-end reads for the MeDIP
samples and 26 million singleton reads for the input
samples with high quality read placements against the
human genome (Maq quality > 10). The mapping of
input reads allowed the efficient detection of genomic
amplifications, including known regions of amplification
(for example, 17q23 and 20q13 in MCF7) [21,22]. We
excluded these regions from the following analyses as
they might result in failure to identify regions with
hypermethylation. Overall, 87% of genomic CpGs all
over the genome were covered by any sample with 12
times depth, the average of each sample’sm a x i m u m
depth (Additional file 1b). Thus, our data sets success-
fully provided non-biased genome-wide information. We
observed that some pairs in the paired-end reads had
identical outer coordinates. As this should happen
rarely, we assumed this to be due to PCR biases intro-
duced by the whole-genome amplification after immu-
noprecipitation. We therefore removed any duplicates
from each data set to improve the overall reproducibility
in the following analyses.
To confirm the reproducibility of the analyses, we
performed two replicates of the MeDIP-seq experi-
ments with HMEC. The numbers of reads overlapping
each CGI and 100 kb genomic segment were highly
correlated between the replicates (r = 0.92 and 0.99,
respectively) (Additional file 1c). To assess whether the
MeDIP-seq analyses correctly identified methylated
regions, we compared MCF7 MeDIP-seq results with
previously reported MCF7 promoter methylome data
generated by the MeDIP-chip technique (deposited in
the public Gene Expression Omnibus database:
GSM263125 [13]). For each probe region, we counted
the number of MeDIP-enriched reads and subtracted
the number of input reads. Overall, regions detected
by MeDIP-seq were found to have higher methylation
levels in MeDIP-chip results., indicating accurate
detection of methylated regions by MeDIP-seq (Addi-
tional file 1d). We also observed considerable hypo-
methylation at some repeat sequences, such as human
satellite II (HSATII, Additional file 1e), known to be
primary targets of hypomethylation in many cancers
[23].
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Page 2 of 11A number of studies have reported that CGIs are
hypermethylated in many cancers [2,12,24]; we therefore
investigated the differential methylation status of CGIs.
C o m p a r e dt oH M E C ,w ef o u n dam o r et h a nf o u r - f o l d
increase in methylation levels in CGIs in many BCC
lines (Additional file 2a). The known hypermethylation
status of many CGIs, for example WT1 [25] and
HOXA5 [26], was confirmed by the MeDIP-seq data
sets (Additional file 2b). We also identified other CGIs
highly methylated in BCC lines and confirmed their
methylation levels using bisulfite sequencing (Additional
file 2c, d). Additionally, we perfomed bisulfite sequen-
cing on randomly chosen regionsto confirm our
MeDIP-seq results (data not shown). We observed a
strong correlation between the MeDIP-seq data and
bisulfite sequencing data, confirming the reliablity of the
MeDIP-seq data (Additional file 2e).
Genomic distribution of aberrant DNA methylation in
BCC lines
We thought it would be useful to obtain overview
methylation maps, albeit at reduced resolution, to
understand the pattern of methylation at the genome-
wide level. We divided the entire genome into 100 kb
segments and counted the number of reads mapped
within each segment. To compare methylation levels
within each sample, the number of reads were normal-
ized against the total number of reads; and the inferred
number of reads per 10 million total reads was calcu-
lated for each sample. The normalized number of reads
in 100 kb regions was clearly correlated to the number
of CpGs in the HMEC MeDIP sample (Additional file
3a), whereas the input sample showed nearly constant
values irrespective of the number of CpGs. Compared to
HMEC, BCC lines showed a lower correlation between
the number of reads and CpGs, suggesting broadly
altered methylation levels in BCC lines.
The number of MeDIP-reads were divided by the
input and used for pairwise comparisons among the
samples, in order to classify each segment as hyper-,
hypo-, and not-differentially methylated groups. We
defined hypermethylation and hypomethylation in BCC
lines as a two-fold increase and decrease, respectively,
in the normalized tag frequency compared to HMEC.
In all BCC lines, hypomethylation occurred 3 to 5
times more frequently than hypermethylation (Figure
1a). Hierarchical clustering showed distinct methyla-
tion patterns of HMEC, compared to BCC lines (Addi-
tional file 3b and 3c). Compared to HMEC, 8.2% of
the segments in BCC lines showed on average a two-
fold decrease in methylation levels (Figure 1b). Next,
we investigated the distribution of hypomethylated and
hypermethylated positions across the entire genome.
Hypomethylated regions in BCC lines were distributed
throughout entire genome, while hypermethylated
regions were clustered at specific loci (1.3% of all seg-
ments), including 16p13.3, 19p13.3, and 9q34.3 (Figure
1c). The number of CpGs within the hypermethylated
and hypomethylated segments was highly biased
toward a lower or higher frequency of CpGs, respec-
tively (Figure 1d). Hypermethylation was also positively
correlated with the number of genes within the seg-
ment region (Figure 1e). All BCC lines showed signifi-
cantly higher methylation levels in gene-rich regions.
In contrast, HMEC showed a lower association
between methylation levels and gene frequency (Addi-
tional file 3d), suggesting that aberrant methylation
preferentially targets genes. We also performed these
analyses using smaller window sizes (~10 kb) and
obtained consistent results (data not shown).
Target position of aberrant methylation in BCC lines
We sought to determine whether the positions of aber-
rantly methylated CpGs were related to genomic fea-
tures. We defined promoter regions as the 10 kb
upstream region of all transcription start sites deposited
in the RefSeq database. Exons and introns were also
defined by this database. The repetitive sequences were
excluded. As ratios could not be determined when
methylated DNA fragments were not detected by
MeDIP-seq in one sample, we evaluated methylation
status by a qualitative criterion in this analysis; we
defined hypermethylation as the region covered by all
BCCs but not by HMEC, and hypomethylation as the
region covered by HMEC but not by any BCCs. We
found that the majority of hypermethylated CpGs were
related to gene promoters, exons and introns (Figure
2a). By contrast, hypomethylated CpGs did not show
significant enrichment of any defined genomic feature.
Hypermethylated CpGs were also found within the
hypomethylated 100 kb segments described above and
were preferentially found at gene-related features (Addi-
tional file 3e). We then investigated the distance
between aberrantly methylated gene-related positions
and transcription start sites (TSS). The CpGs around
TSS were classified into promoters, exons and introns,
and then we calculated their distances to TSS. Hyper-
and hypomethylated CpGs tended to be concentrated in
regions proximal to TSS, suggesting that these regions
are important for the regulation of gene expression (Fig-
ure 2b). Since the density of CpGs was highest at
r e g i o n sp r o x i m a lt oT S S ,t h er e l a t i v ef r e q u e n c i e so f
hyper- and hypomethylations at distal regions were
higher than proximal regions, when considering the
ratio with the CpG content. We also analyzed the distri-
bution of the distance from transcription start sites to
hyper- and hypomethylated CpGs in CpG islands (Addi-
tional file 4a) and found that relative frequencies of
Ruike et al. BMC Genomics 2010, 11:137
http://www.biomedcentral.com/1471-2164/11/137
Page 3 of 11Figure 1 BCCs undergo massive overall loss of methylation. (a) The number of differentially methylated 100 kb segments were counted for
each cell lines. (b) Log scaled scatter plot of the MeDIP/Input ratio in each 100 kb segments for HMEC and BCCs (for BCCs the average ratio is
shown). The red and green dots show hyper- and hypomethylation respectively. The dashed line shows a diagonal line. (c) Genome-wide
distribution of hyper- or hypomethylated regions. Red bars indicate hypermethylated regions and green bars indicate hypomethylated regions.
Circles indicate centromeres. (d) The distribution of the number of CpGs within hyper- or hypomethylated regions. (e) The distribution of the
number of genes within hyper- or hypomethylated regions.
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Page 4 of 11Figure 2 Hypermethylations are associated with CpG-rich and gene-related regions. (a) Pie chart representing the proportions of each
genomic features of hyper- or hypomethylated CpGs. The repeats are not included when considering subsequent features. Promoters are
defined as 10 kb regions from transcriptional start sites annotated in RefSeq database. (b) Distribution of the distance from transcription start
sites to differentially methylated sites. CpG density is shown as a black line. Dotted lines show the ratio of hyper- or hypomethylated CpGs to
CpG density. (c) Distribution of CpGo/e ratios surrounding CpGs covered in each MeDIP samples. (d) Distribution of CpGo/e ratios surrounding
hyper- or hypomethylated CpGs in BCCs.
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Page 5 of 11hypermethylations at distal regions were higher than
proximal regions.
To examine the effect of methylations both proximal
and distal to TSS on gene expression, we performed a
correlation analysis between methylation patterns and
gene expression. The gene expression profiles of six
BCC lines (Hs578T, MCF7, MDAMB231, MDAMB453,
SKBR3, T47D) were obtained from a public database
(Gene Expression Omnibus: GSE12777) [27]. Regions
around TSS (+/- 10 kb) were divided into 1 kb segments
and the number of reads within each segment was
counted for each sample. The fraction of genes with
expressions positively correlated to methylation patterns
was higher at distal regions (Additional file 4b). On the
other hand, the fraction of genes with expressions nega-
tively correlated was higher at proximal regions,
although the fraction of negatively correlated genes were
lower than positively correlated genes at any distance
from TSS.
Aberrant methylations at CpG-rich regions in BCCs
As described above, hypermethylation was associated with
CGIs. However, the hypermethylation observed at gene-
related regions was not limited to predefined CGIs (Addi-
tional file 5a): 53% of hypermethylated CpGs in BCC lines
belonged to non-CGI regions. Our observations therefore
challenge the current presumption that hypermethylation
is restricted to CGIs and proximal promoters. We investi-
gated the characteristics of hypermethylated CpGs across
the entire genome by counting the number of neighboring
CpGs within the 500 bp regions surrounding hypermethy-
lated sites and calculated the CpG observed/expected ratio
(CpGo/e) [1] for each CpG.
To screen for association between CpGo/e and aber-
rant methylation targets, we examined the CpGo/e distri-
bution across all CpGs covered by each MeDIP sample.
The CpGo/e ratio distribution of CpGs that belonged to
promoter regions was divided into two distinct classes
at the CpGo/e ratio 0.6, which is also the criterion for
CGIs [1,28]. The promoter CpGs covered in HMEC
were considerably biased towards a low ( < 0.6) CpGo/e
ratio (Figure 2c and Additional file 5b). On the other
hand, CpGs with a high (>0.6) CpGo/e ratio were highly
covered by all BCC lines. We also found that hyper-
methylation of a CpG-rich region was more likely to be
shared by BCC lines, compared to that in a CpG-poor
region (Additional file 5c). By contrast, hypomethylation
in a CpG-poor region was more likely to be shared by
BCC lines, compared to that in CpG-rich region. We
then defined the hypermethylated CpGs that were cov-
ered in all BCC lines but not in HMEC, and hypomethy-
lated CpGs that were covered in HMEC but not in all
BCC lines. Hypermethylation was mainly observed in
CpGs with a high CpGo/e ratio, and hypomethylation
was highly biased towards CpGs with a low CpGo/e ratio
(Figure 2d). Hypermethylation was also observed at
exons and introns in high CpGo/e regions.
EMT-induced methylome alteration
According to the epithelial-mesenchymal transition
(EMT) hypothesis, BCCs undergo phenotype alterations
during the sequential in vivo progression of cancer from
atypical hyperproliferation to metastatic disease, sub-
tended or not by genetic changes [29,30]. Although
altered methylations of some gene promoters have been
reported to be one of the principal causes of EMT
[31,32], the relationship between the epithelial-mesench-
ymal phenotype of breast cancers and the genome-wide
methylation profile remains unclear. Here, we screened
for genome-wide methylome alterations during EMT
induction in MCF7. Treatment with TGFb and TNFa
efficiently altered the normal epithelial phenotype of
MCF7 cells to a mesenchymal phenotype. Pairwise com-
parisons of normalized methylation levels in 100 kb seg-
ments revealed that EMT had little effect on the global
distribution of DNA methylation (Figure 3a). However,
compared to normal MCF7 cells, the percentage of
reads covering CGIs was reduced following induced
EMT (Figure 3b). EMT induction was associated with a
massive loss of hypermethylated CGIs and gain of hypo-
methylated CGIs (Figure 3c). Furthermore, EMT induc-
tion more frequently resulted in hypomethylation rather
than hypermethylation at gene-related CpGs (Figure 3d),
and EMT-induced hypomethylation was predominant
especially at CpG-rich regions (Figure 3e).
We also investigated whether EMT-induced methy-
lome alterations in CpG-rich regions were associated
with epithelial- or mesenchymal-specific patterns of
methylation. Based on the phenotypic classification of
cell lines into epithelial (HMEC, MCF7 and T47D) and
mesenchymal (HMC18, Hs578T and MDAMB231) [29],
epithelial- or mesenchymal-specific methylation patterns
were determined. Approximately 40% of epithelial-speci-
fic methylation sites were hypomethylated following
EMT-induction, while only 10% of total sites were hypo-
methylated (Figure 3f). In addition, approximately 40%
of mesenchymal-specific methylation sites were hyper-
methylated following EMT-induction, while only ~10%
of total sites were hypermethylated. These cell-type spe-
cific methylome alterations were found in all gene-
related regions. Although these changes are partial, the
results suggest that EMT-induction affects the morpho-
logical phenotype of the cells through methylome altera-
tions within CpG-rich regions.
Discussion
This study provides the first comprehensive, detailed
map of DNA methylation patterns in human mammary
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Page 6 of 11Figure 3 EMT-induced methylome alterations in MCF7. (a) Log scaled scatter plot displaying the association between the MeDIP/Input ratio
of 100 kb segments in EMT-induced MCF7 and each cell lines. (b) Bar plot displaying the percentage of reads covering CGIs in EMT-induced or
control MCF7. (c) The number of hyper- or hypomethylated CGIs gained or lost through EMT-induction in MCF7. (d) Bar plot displaying the
percentage of hyper- or hypomethylated CpGs within each gene-related regions. (e) Distribution of CpGo/e surrounding CpGs, hyper- or
hypomethylated through EMT. (f) Bar plot displaying the percentage of hyper- or hypomethylated CpGs within cell-type specifically methylated
regions.
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Page 7 of 11cell lines. Methylated DNA fragments were detected
using a highly sensitive method involving enrichment by
MeDIP, and high-throughput sequencing enabled the
non-biased mapping of aberrant methylation sites across
the genomes of BCC lines. We examined 10 different
cell populations in total, including EMT-induced MCF7
cells, to investigate the association between DNA
methylome alterations and changes in cellular morpho-
logical phenotypes. Our data sets covered almost the
entire genome with sufficient depth to identify differen-
tially methylated regions, thereby providing high resolu-
tion and reproducibility, and proved that MeDIP-seq is
a cost-effective approach for comparative analyses of the
mammalian DNA methylome. Although many research-
ers have sought to describe DNA methylome alterations
in cancers, to our knowledge this is the first methylome
study that effectively encompasses the entire genome
and is not limited to specific sequences. This study has
thus provided important new insights into the biological
implications of DNA methylation.
Firstly, the global methylation map provides an indica-
tion of the intricate relationship between the methylome
and transcriptome. Most cancer methylome studies have
assumed that functionally important DNA methylation
is restricted to promoters and that most DNA methyla-
tion changes in cancer occur in CGIs, and they ignore
all other regions. In our analysis, although hypermethy-
lation at predefined CGIs was a remarkable feature of
the BCC lines, we also found that many non-CGI
regions were broadly hypermethylated. Hypermethyla-
tion occurred not only at proximal promoters but also
at exons and introns, including regions distal from the
TSS. Since DNA methylation interrupts the binding of
transcription factors to their response elements [2,11],
changes in methylation at distal regions may affect the
expression of a gene. Since proximal promoters or CGI
methylation are not always correlated with gene expres-
sion [13,33], our comprehensive methylation maps will
help us to better understand methylation-dependent
transcriptional regulation.
Secondly, the comprehensive methylation maps help
us to understand how methylation is maintained and
how it is disrupted in BCC lines. We found that the
number of reads was positively correlated with the num-
ber of CpGs within 100 kb segments and this relation-
ship was especially clear in HMEC. Although HMEC
showed relatively low methylation levels in gene-related
CpG-rich regions (corresponding to less than 8% of
whole-genome CpGs), overall, methylation of each CpG
seemed to be maintained at a nearly constant level. The
most prominent feature of aberrant methylation was the
massive overall hypomethylation and simultaneous
hypermethylation at CpG-rich regions. While these
observations are consistent with previous reports [11],
our results provide the most detailed map of aberrant
methylation in BCC lines. We found that hypomethyla-
tion in BCC lines was biased towards CpG-poor regions,
and analysis of genomic features indicated there was no
preference for repeat sequences but included all gene-
related regions equally. Furthermore, hypermethylations
of CpG-rich gene-related regions was present in BCC
lines although within extremely hypomethylated 100 kb
segments. These results support the idea that there are
at least two distinct maintenance mechanisms that pro-
duce the aberrant methylation patterns in CpG-poor
regions and CpG-rich regions. One mechanism main-
tains CpGs at a constant methylation level, which is
downregulated in BCC lines. Another mechanism main-
tains gene-related CpG-rich regions at a specific methy-
lation level, which is generally upregulated in BCC lines.
Finally, the comparative analysis of methylation maps
of MCF7 cells with or without EMT induction provided
an increased understanding of how cells undergo DNA
methylome alterations. Analysis of 100 kb segments
revealed almost unchanged overall methylation levels
throughout EMT, while hypomethylation was observed
at many CGI sites. With respect to the two distinct
mechanisms of methylome alteration described above,
EMT had little effect on the maintenance of the overall
methylation level, but had a considerable effect on cell-
type specific methylation. On the other hand, EMT
induction altered cell-type specific gene-related methyla-
tion such that hypomethylation was predominantly
observed at CpG-rich regions. The idea that there are
cell-type and gene specific mechanisms for regulation of
methylation patterns within CpG-rich gene-related
regions received further support from the following
observations. The methylation status within CpG-rich
regions were likely to be shared by BCC lines, and CpGs
within CpG-rich repetitive sequences such as HSATII
were extensively hypomethylated in BCC lines. Consid-
ering that the methylation status participates in deter-
mining the morphological phenotypes of the cells
[7,28,29], our results suggested an interdependence
between cell-type and gene specific regulation of DNA
methylations and morphological changes during EMT.
Conclusions
We performed a comprehensive methylation profiling of
human mammary cell lines using the MeDIP-seq analy-
sis, revealing aberrant methylation patterns in BCC lines
and EMT-induced alteration of the methylome. Methy-
lome alteration in BCC lines had two principal charac-
teristics: a downregulated overall level of CpG
methylation; and cell-type specific regulation of DNA
methylation at gene-related CpG-rich regions. Our
results provide important insights into the mechanisms
of methylome alterations during tumor development.
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Cell lines
HMEC (CC-2551, Lonza) was cultured using the med-
ium supplied by MEGM Bullet Kit (CC-3150, Lonza) at
37°C and 5% CO2.M C F 7 ,M D A M B 2 3 1 ,S K B R 3 ,a n d
T47D were kindly gifted by Dr. Masakazu Toi (professor
of Kyoto University Hospital Breast Surgery Depart-
ment) and cultured in RPMI 1640 medium (Invitrogen)
containing 10% FBS. Hs578T (86082104, European Col-
lection of Cell Culture) and MDAMB453 (RCB1192,
RIKEN BioResource Center) were cultured in DMEM
containing 10% FBS. HMC-1-8 and MRK-nu-1
(JCRB0166 and JCRB0628 respectively, Health Science
Research Resources Bank) were cultured in RPMI 1640
medium (Invitrogen) containing 10% FBS.
Bisulfite-modified DNA sequencing
We prepared genomic DNA from cultured cells using the
Gentra Puregene Cell kit (Qiagen). Approximately 2 μgo f
DNA was bisulfite-treated with the EpiTect Bisufite kit
according to the manufacturer’s protocol (Qiagen). Ampli-
fication across the entire bisulfite converted genome was
performed by the EpiTect Whole Bisufitome kit according
to the manufacturer’s protocol (Qiagen). Nested PCR was
performed on bisulfite-modified DNA using the following
primers; IRX1firstF: GTTTTTGTATATTTGGTGGA,
IRX1firstR: CAACTATCTAACAACCTATC, IRX1nes-
tedF: TTTTTGGGTGAAGAGAAAGT, IRX1nestedR:
CCCTTTTTAACAAAAACAAC, PAX7firstF: GGG-
AGTTTTATTGGAGGAAT, PAX7firstR: ACTCCC-
TCCCTCTTCTCCAC, PAX7nestedF: GAGAAGAT-
GAGAAATAGGGT, PAX7nestedR: TCCACACCAAC-
TTTCACAAC.
Methyl-DNA immunoprecipitation
Before carrying out MeDIP, we sonicated genomic
DNA to produce random fragments ranging in size
from 200 to 600 bp. We used 4 mg of fragmented
DNA for a standard MeDIP assay as described [14].
Briefly, following denaturation at 95°C for 10 min,
immunoprecipitation was carried at 4°C for 2 hr using
10 μg of monoclonal antibody against 5-methylcytidine
(315-80541, Diagenode) in a final volume of 500 μlI P
buffer (10 mM sodium phosphate (pH 7.0), 140 mM
NaCl, 0.05% Triton X-100). We incubated the mixture
with 40 μl of Dynabeads and M-280 sheep antibody to
mouse IgG (Dynal Biotech) for 12 hr at 4°C and
washed it seven times with 700 μlo fI Pb u f f e r .W e
then treated the beads with proteinase K for 4 hr
at 50°C and recovered the methylated DNA by
phenol-chloroform extraction followed by ethanol
precipitation.
Illumina Genome Analyzer sequencing
We performed second strand synthesis of MeDIP-
enriched single-strand DNA fragments. Samples contain-
ing ~200 ng of DNA and 500 ng of random primer at a
final volume of 57.9 μl were incubated at 70°C for 10 min,
followed by gradual cooling for 40 min. Two ml of 2.5
mM each dNTPs, 20 μlo f5 ×s e c o n ds t r a n db u f f e r( 1 0 0
mM Tris-HCl (pH 7.5), 500 mM potasium chloride, 25
mM magnesium chloride, 50 mM ammonium sulphate,
and 250 mg/ml bovine serum albumin), 10 μl of 100 mM
dithiothreitol, 3 μl of 5 mM beta-NAD+, 0.5 μl( 5U )o fE.
coli DNA ligase (TaKaRa Bio), and 6.6 μl (25 U) of E. coli
DNA polymerase I (TaKaRa Bio) were then added to the
sample (100 μl final volume). The reaction was performed
at 14°C for 12 hr. Next, we purified double-stranded DNA
fragments using the PCR purification kit (Qiagen). The
end-repair of DNA fragments, addition of an adenine to
the 3’ ends of DNA fragments, adaptor ligation, and PCR
amplification by Illumina paired-end PCR primers were
performed as described previously [14]. We performed gel
electrophoresis and excised bands from the gel to produce
libraries with insert sizes of 250~350 bp, and quantified
these libraries using the Quant-iT PicoGreen dsDNA
Reagent and Kits (Invitrogen). We then prepared flowcells
with 8 pM DNA using the manufacture’s recommended
protocol and sequenced for 36 cycles on an Illumina Gen-
ome Analyzer II. Obtained images were analyzed and
base-called using GA pipeline software version 1.3 with
default settings provided by Illumina. MeDIP-seq data
from this study have been submitted to DDBJ Read
Archive database http://trace.ddbj.nig.ac.jp/dra/index_e.
shtml under accession number “DRA000030”.
Mapping reads
We downloaded the human genome sequence and map-
ping information (Mar. 2006, hg18) from the University
of California Santa Cruz Genome Bioinformatics Site
http://genome.ucsc.edu. The reads were mapped onto
the human genome reference sequence using the high-
performance alignment software ‘maq’ version 0.7.1
http://maq.sf.net[17]. The reads with maq quality less
than 10 were removed from further analysis. We consid-
ered each singleton read as a 250 bp block extended from
t h es i n g l er e a d ’s mapping position on its strand, repre-
senting an entry for MeDIP-enriched DNA fragments.
EMT-induction
MCF7 cells were plated at 3 × 10
4 cells/ml in 12 well
plates and incubated for 24 hr. Cells were then treated
with 2 ng/ml of TGFb and 10 ng/ml of TNFa for five
days [34]. EMT-induction wasc o n f i r m e db ym o r p h o l o -
gical alterations and the detection of downregulated
Ruike et al. BMC Genomics 2010, 11:137
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Page 9 of 11epithelial marker expression and upregulated mesench-
ymal marker expression using reverse transcription
PCR.
Additional file 1: Supplemental Figure 1. A figure showing effieient
detection of methylation by MeDIP-seq.
Additional file 2: Supplemental Figure 2. A figure showing aberrant
methylation patterns of CGIs in BCCs.
Additional file 3: Supplemental Figure 3. A figure showing the
correlation between the normalized number of reads and the number of
CpGs and genes within 100 kb genomic segments.
Additional file 4: Supplemental Figure 4. A figure showing aberrant
methylation at the region distal from TSS.
Additional file 5: Supplemental Figure 5. A figure showing differently
regulated methylation of CpG-poor and CpG-rich regions.
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